Core Insights - Addex Therapeutics reported its financial results for Q3 and YTD 2025, highlighting a focus on developing novel small molecule allosteric modulators for neurological disorders [1][4] Financial Performance - Income for Q3 2025 was CHF 50,000, a decrease of CHF 8,000 from Q3 2024, and year-to-date income was CHF 157,000, down CHF 251,000 compared to the same period in 2024 [3] - R&D expenses increased to CHF 228,000 in Q3 2025 from CHF 204,000 in Q3 2024, while year-to-date R&D expenses decreased to CHF 619,000 from CHF 789,000 [3][5] - G&A expenses for Q3 2025 were CHF 518,000, up from CHF 476,000 in Q3 2024, with year-to-date G&A expenses decreasing to CHF 1,573,000 from CHF 1,929,000 [3][6] - The total operating loss for Q3 2025 was CHF 696,000, compared to CHF 622,000 in Q3 2024, with a year-to-date total operating loss of CHF 2,035,000, an improvement from CHF 2,310,000 [3] - Net loss from continuing operations for Q3 2025 was CHF 1,577,000, slightly higher than CHF 1,528,000 in Q3 2024, while year-to-date net loss increased to CHF 5,009,000 from CHF 3,720,000 [3][8] - Basic and diluted net loss per share for the nine-month period was CHF 0.05, compared to a profit of CHF 0.08 in the same period of 2024 [9] Cash Position - Cash and cash equivalents decreased to CHF 2.2 million as of September 30, 2025, from CHF 3.3 million a year earlier, primarily due to operating activities [10] Corporate Developments - The company is advancing its GABAB positive allosteric modulator candidate for chronic cough and dipraglurant for post-stroke recovery [2][14] - Addex holds a 20% equity interest in Neurosterix US Holdings LLC, which is developing a portfolio of allosteric modulator programs [14]

Core Insights - Addex Therapeutics announced that its partner Indivior has successfully advanced the GABAB positive allosteric modulator (PAM) program through IND enabling studies, marking the final preclinical development stage before clinical studies can commence [1][2] - Addex is eligible for payments up to USD 330 million based on the achievement of regulatory, clinical, and commercial milestones, along with tiered royalties on net sales ranging from high single digits to low double digits [2] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4] - The company's lead drug candidate, dipraglurant, is under evaluation for brain injury recovery, including post-stroke and traumatic brain injury recovery [4] - Addex holds a 20% equity interest in Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs for various neurological conditions [4] GABAB PAM Program - The GABAB PAM program is aimed at treating substance use disorders and has successfully completed preclinical safety and toxicity studies [2][3] - The activation of the GABAB receptor is clinically validated, with existing agonists like baclofen showing efficacy in multiple disease areas, although their use is limited due to side effects [3] - Novel PAMs are expected to provide efficacy with fewer adverse effects and less tolerance compared to direct agonists [3]